Bacitracin
Name: Bacitracin
- Bacitracin bacitracin brand name
- Bacitracin names
- Bacitracin brand name
- Bacitracin bacitracin drug
- Bacitracin drug
- Bacitracin bacitracin dosage
- Bacitracin dosage
- Bacitracin injection
Overdose
No information provided.
Bacitracin Brand Names
Bacitracin may be found in some form under the following brand names:
AK-Tracin
Atopalm First Aid
Atopalm First Aid Moisturizing and Pain Relief
Baci-IM
Baciguent
Bacitraycin Plus
Betadine Antibiotic
Betadine Plus Antibiotic and Pain Reliever
Campho-Phenique Maximum Strength
Cortisporin Ointment
Cortomycin Ointment
Lanabiotic
Medi-Quik
Mycitracin Plus Pain Reliever
Mycitracin Triple Antibiotic
Neo-Polycin
Neo-Polycin HC
Neocidin Ointment
Neocin
Neosporin Ointment
Neosporin Plus Maximum Strength
Neosporin Plus Maximum Strength Ointment
Neotricin HC
Ocu-Cort
Ocu-Spore-B
Ocu-Tracin
Ocumycin
Ocutricin
Polycin-B
Polysporin
Polytracin
ProCoMycin
Rash Relief Antibacterial
Repara Triple Antibiotic
Septa
Spectrocin Plus
Tri Biozene
Tribiotic Plus
Bacitracin Drug Class
Bacitracin is part of the drug class:
OTHER ANTIBACTERIALS
Uses for Bacitracin
Staphylococcal Pneumonia and Empyema in Infants
Has been used IM in infants for treatment of pneumonia and empyema caused by susceptible staphylococci.100 104
Not considered a preferred or alternative agent for treatment of staphylococcal infections; other anti-infectives are used for treatment of staphylococcal respiratory tract infections.137 138 139
Manufacturers state use bacitracin only when adequate laboratory facilities are available and constant supervision of the patient is possible.100 104
Clostridium difficile-associated Diarrhea and Colitis (CDAD)
Has been used orally† for treatment of CDAD† (also known as antibiotic-associated diarrhea and colitis or pseudomembranous colitis).101 102 103 110 111 112 113 117 140 143 Designated an orphan drug by FDA for use in this condition.114
Oral bacitracin not recommended as a preferred or alternative agent for treatment of C. difficile infection (CDI) or CDAD.110 111 112 113 Bacitracin-resistant C. difficile reported,111 113 and the drug generally has been less effective that other anti-infectives used in management of CDAD.110 111 112 113 In addition, bacitracin oral preparations not commercially available in US.
Bacitracin Dosage and Administration
Administration
Administer IM.100 104
Has been administered orally†,101 102 103 112 113 117 140 143 but oral preparations not commercially available in US.
IM Injection
Inject into upper outer quadrant of the buttocks.100 104 Alternate injection sites between right and left side.100 104 Avoid making multiple injections in same region because of transient pain following injection.100 104
ReconstitutionReconstitute lyophilized powder for injection by dissolving in 0.9% sodium chloride injection containing 2% procaine hydrochloride.100 104 If 9.8 mL of this diluent is used to reconstitute a vial containing 50,000 units of bacitracin, resultant solution contains 5000 units/mL.100 104
Do not use bacitracin solutions containing <5000 units/mL or >10,000 units/mL.100 104
Do not use diluents containing parabens;100 104 cloudy solutions and precipitate formation may occur.100 104
Dosage
Pediatric Patients
Staphylococcal Pneumonia and Empyema in Infants IMInfants <2.5 kg: Manufacturers recommend 900 units/kg daily given in 2 or 3 divided doses.100 104
Infants >2.5 kg: Manufacturers recommend 1000 units/kg daily in 2 or 3 divided doses.100 104
Prescribing Limits
Pediatric Patients
Staphylococcal Pneumonia and Empyema in InfantsDo not exceed recommended dosage;100 104 duration >12 days not recommended.a
Special Populations
No special population dosage recommendations.100 104
Interactions for Bacitracin
Specific Drugs
Drug | Interaction | Comments |
---|---|---|
Aminoglycosides (kanamycin, neomycin, streptomycin) | Possible additive nephrotoxic effects14 | Avoid concomitant use14 100 104 |
Colistimethate/colistin | Possible additive nephrotoxic effects14 | Avoid concomitant use14 100 104 |
Polymyxin b sulfate | Possible additive nephrotoxic effects14 100 104 | Avoid concomitant use14 100 104 |
Neuromuscular blocking agents and general anesthetics | Possible enhanced neuromuscular blockade if bacitracin used concomitantly during surgery or postoperatively14 | |
Vancomycin | Possible additive nephrotoxic effects14 | Avoid concomitant use14 100 |
Preparations
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.
* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name
Routes | Dosage Forms | Strengths | Brand Names | Manufacturer |
---|---|---|---|---|
Parenteral | For injection, for IM use | 50,000 units* | BACiiM | X-Gen |
Bacitracin for Injection |
PACKAGE/LABEL PRINCIPAL DISPLAY PANEL – 3.5 g Carton
Rx Only
NDC 0574-4022-35
Bacitracin Ophthalmic Ointment USP
NET WT 3.5 g (1/8 oz)
STERILE